Miv-150-containing intravaginal rings protect macaque vaginal explants against shiv-rt infection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2841-2848

  Ouattara, Louise A ^a   Barnable, Patrick ^a   Mawson, Paul ^a   Seidor, Samantha ^a   Zydowsky, Thomas M ^a   Kizima, Larisa ^a   Rodriguez, Aixa ^a   Fernández Romero, José A ^a   Cooney, Michael L ^a   Roberts, Kevin D ^a   Gettie, Agegnehu ^b   Blanchard, James ^c   Robbiani, Melissa ^a   Teleshova, Natalia ^a  

^a POPULATION COUNCIL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIV 150; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; PYRIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BIOPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; DRUG TISSUE LEVEL; EX VIVO STUDY; EXPLANT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN HXB2); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; UTERINE CERVIX; VAGINA; VAGINA DISCHARGE; VAGINA RING; ANALOGS AND DERIVATIVES; ANIMAL; INTRAVAGINAL DRUG ADMINISTRATION; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; FEMALE; MACACA; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; UREA;

EID: 84898645158     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01529-13     Document Type: Article

References (49)

1. Derby N, Zydowsky T, Robbiani M. 2013. In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward? Expert Rev. Anti Infect. Ther. 11:5-8. http://dx.doi.org/10.1586/eri.12.155.
2. Smith DJ, Wakasiaka S, Hoang TD, Bwayo JJ, Del Rio C, Priddy FH. 2008. An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J. Womens Health (Larchmt.) 17: 1025-1034. http://dx.doi.org/10. 1089/jwh.2007.0529.
3. Shattock RJ, Rosenberg Z. 2012. Microbicides: topical prevention against HIV. Cold Spring Harb. Perspect. Med. 2:a007385. http://dx.doi.org/10.1101/ cshperspect.a007385.
4. Malcolm RK, Fetherston SM, McCoy CF, Boyd P, Major I. 2012. Vaginal rings for delivery of HIV microbicides. Int. J. Womens Health 4:595-605. http://dx.doi.org/10.2147/IJWH.S36282.
5. Thurman AR, Clark MR, Hurlburt JA, Doncel GF. 2013. Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int. J. Womens Health 5:695-708. http://dx.doi.org/10.2147/IJWH.S34030.
6. Montgomery ET, van der Straten A, Cheng H, Wegner L, Masenga G, von Mollendorf C, Bekker L, Ganesh S, Young K, Romano J, Nel A, Woodsong C. 2012. Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 16:1787-1798. http://dx.doi.org/10.1007/s10461-012-0248-4.
7. Friend DR, Kiser PF. 2013. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res. 99: 391-400. http://dx.doi.org/10.1016/j.antiviral.2013.06.021.
8. AVAC. 2012. Ongoing and planned clinical trials of microbicide candidates. AVAC, New York, NY. http://www.avac.org/ht/a/GetDocument Action/i/3109.
9. Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, Clark JT, Fabian J, McCabe RT, Chandra N, Doncel GF, Friend DR, Kiser PF. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob. Agents Chemother. 56:6272-6283. http://dx.doi.org/10.1128/AAC.01431-12.
10. Karim SS, Kashuba AD, Werner L, Karim QA. 2011. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378:279-281. http://dx.doi.org/10.1016/S0140- 6736(11)60878-7.
11. Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja U, McNicholl JM, Hendry RM, Dinh CT, Martin A, Herold BC, Kiser PF. 2013. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc. Natl. Acad. Sci. U. S. A. 110:16145-16150. http://dx.doi.org/10.1073/pnas.1311355110.
12. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, Lewi P, Vanham G, Janssen P. 2004. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48:337-339. http://dx.doi.org/10.1128/AAC.48.1.337-339.2004.
13. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, Temmerman M, Verstraelen H, Van Bortel L, Weyers S, Mitchnick M. 2009. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses 25:483-488. http://dx.doi.org/10.1089/aid.2008.0184.
14. Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, Menon R, Goldman D, Kenney J, Aravantinou M, Seidor S, Gettie A, Blanchard J, Piatak M, Jr, Lifson JD, Fernandez-Romero JA, Robbiani M, Zydowsky TM. 2012. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci. Transl. Med. 4:150ra123. http://dx.doi.org/10.1126/scitranslmed.3003936.
15. Turville SG, Aravantinou M, Miller T, Kenney J, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Piatak M, Jr, Bess JW, Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M. 2008. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 3:e3162. http://dx.doi.org/10.1371/ journal.pone.0003162.
16. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R. 2008. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med.5:e157. http://dx.doi.org/ 10.1371/journal.pmed.0050157.
17. Kenney J, Aravantinou M, Singer R, Hsu M, Rodriguez A, Kizima L, Abraham CJ, Menon R, Seidor S, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M, Jr, Fernandez-Romero JA, Zydowsky TM, Robbiani M. 2011. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 6:e15835. http://dx.doi.org/10.1371/journal. pone.0015835.
18. US Department of Agriculture. 2001. Animal Welfare Act and Regulation of 2001. Code of Federal Regulations, t., chapter 1, subchapter A: animals and animal products. US Department of Agriculture, Beltsville, MD.
19. Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources. 1985. Guide for the care and use of laboratory animals. Publication no. 85-23:1-83. US Department of Health and Human Services, National Institutes of Health, Bethesda, MD.
20. Singer R, Derby N, Rodriguez A, Kizima L, Kenney J, Aravantinou M, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M, Jr, Fernandez-Romero JA, Zydowsky TM, Robbiani M. 2011. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J. Virol. 85:5504-5512. http://dx.doi.org/10.1128/JVI.02422-10.
21. Crostarosa F, Aravantinou M, Akpogheneta OJ, Jasny E, Shaw A, Kenney J, Piatak M, Lifson JD, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Blanchard J, Gettie A, Robbiani M. 2009. A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One 4:e8060. http://dx.doi.org/10.1371/journal.pone.0008060.
22. Aravantinou M, Singer R, Derby N, Calenda G, Mawson P, Abraham C, Menon R, Seidor S, Goldman D, Kenney J, Villegas G, Gettie A, Blanchard J, Lifson J, Piatak M, Fernandez-Romero JA, Zydowsky T, Teleshova N, Robbiani M. 2012. The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT infection. AIDS Res. Hum. Retroviruses 28:1467-1475. http://dx.doi.org/10.1089/aid.2012.0080.
23. Richardson-Harman N, Mauck C, McGowan I, Anton P. 2012. Doseresponse relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res. Hum. Retroviruses 28:1422-1433. http://dx.doi.org/10.1089/aid.201 2.0073.
24. Richardson-Harman N, Lackman-Smith C, Fletcher PS, Anton PA, Bremer JW, Dezzutti CS, Elliott J, Grivel JC, Guenthner P, Gupta P, Jones M, Lurain NS, Margolis LB, Mohan S, Ratner D, Reichelderfer P, Roberts P, Shattock RJ, Cummins JE, Jr. 2009. Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J. Clin. Microbiol. 47:3530-3539. http://dx.doi.org/10.1128/JCM.00673-09.
25. Kumar N, Didolkar AK, Ladd A, Thau R, Monder C, Bardin CW, Sundaram K. 1990. Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. J. Steroid Biochem. Mol. Biol. 37:587-591. http://dx.doi.org/10.1016/0960-0760(90)90405-A.
26. Balzarini J, Weeger M, Camarasa MJ, De Clercq E, Uberla K. 1995. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem. Biophys. Res. Commun. 211:850-856. http://dx.doi.org/10.1006/bbrc.1995. 1890.
27. Balzarini J, De Clercq E, Uberla K. 1997. SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15:1-4. http://dx.doi.org/10.1097/00042560-199705010-00001.
28. Jiang Y, Tian B, Agy MB, Saifuddin M, Tsai CC. 2009. Macaca fascicularis are highly susceptible to an RT-SHIV following intravaginal inoculation: a new model for microbicide evaluation. J. Med. Primatol. 38(Suppl 1):39-46. http://dx.doi.org/10.1111/j.1600-0684.2009.00374.x.
29. Pal R, Nuttall J, Galmin L, Weiss D, Chung HK, Romano J. 2009. Characterization of vaginal transmission of a simian human immunodeficiency virus (SHIV) encoding the reverse transcriptase gene from HIV-1 in Chinese rhesus macaques. Virology 386:102-108. http://dx.doi.org/10.1016/j.virol.2009. 01.002.
30. Jiang Y, Tian B, Saifuddin M, Agy MB, Emau P, Cairns JS, Tsai CC. 2009. RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res. Ther. 6:23. http://dx.doi.org/10.1186/1742-6405-6-23.
31. Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, Wu Z, Mayer K, Wright PF, Kappes JC, Ochsenbauer C, Wira CR. 2010. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 5:e11366. http://dx.doi.org/ 10.1371/journal.pone.0011366.
32. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, Challacombe SJ. 2006. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin. Vaccine Immunol. 13:1111-1118. http://dx.doi.org/10.1128/CDLI.00426-05.
33. Levinson P, Choi RY, Cole AL, Hirbod T, Rhedin S, Payne B, Guthrie BL, Bosire R, Cole AM, Farquhar C, Broliden K. 2012. HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships. PLoS One 7:e31996. http://dx.doi.org/10.1371/ journal.pone.0031996.
34. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, Mahoney CJ, Miller CJ, Claypool LE, Ho DD, Alexander NJ. 1996. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2:1084-1089. http://dx.doi.org/10.1038/nm1096-1084.
35. Anderson DJ, Pudney J, Schust DJ. 2010. Caveats associated with the use of human cervical tissue for HIV and microbicide research. AIDS 24:1-4. http://dx.doi.org/10.1097/QAD.0b013e328333acfb.
36. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C, Karim SS, Masse B, Perriens J, Laga M. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977. http://dx.doi.org/10.1016/S0140-6736(02) 11079-8.
37. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, Anzala A, Holton D, Plummer F. 1992. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268:477-482. http://dx.doi.org/10.1001/jama.1992.03490040053025.
38. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987. http://dx.doi.org/10.1016/S0140-6736(08)61842-5.
39. Cummins JE, Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA, Paxton L, Dezzutti CS. 2007. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob. Agents Chemother. 51:1770-1779. http://dx.doi.org/10.1128/AAC.01129-06.
40. Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, Buckheit RW, Jr, Watson K, Dezzutti CS, Cummins JE, Bromley E, Richardson-Harman N, Pallansch LA, Lackman-Smith C, Osterling C, Mankowski M, Miller SR, Catalone BJ, Welsh PA, Howett MK, Wigdahl B, Turpin JA, Reichelderfer P. 2006. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob. Agents Chemother. 50:713-723. http://dx.doi.org/10.1128/AAC.50.2. 713-723.2006.
41. Dezzutti CS, Hladik F. 2013. Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities. Curr. HIV/AIDS Rep. 10:12-20. http://dx.doi.org/10.1007/s11904-012-0148-2.
42. Microbicides Development Programme. 2009. The MDP 301 trial. Microbicides Development Programme, Medical Research Council, London, United Kingdom. http://www.mdp.mrc.ac.uk/archive.html.
43. Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, Guzman E, Wang R, Herold BC, Keller MJ. 2007. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J. Infect. Dis. 196:1394-1402. http://dx.doi.org/10. 1086/522606.
44. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Masse B, Hillier SL, Soto-Torres L. 2011. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25:957-966. http://dx.doi.org/10.1097/QAD.0b013e32834541d9.
45. Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, Elliott J, Janocko L, Khanukhova E, Dennis R, Cumberland WG, Ju C, Carballo-Dieguez A, Mauck C, McGowan I. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses 28:1412-1421. http://dx.doi.org/10.1089/aid.2012.0262.
46. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS. 2010. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 5:e9310. http://dx.doi.org/10.1371/ journal.pone.0009310.
47. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174. http://dx.doi.org/10.1126/science. 1193748.
48. Microbicide Trials Network. 2013. The results of VOICE: Vaginal and Oral Interventions to Control the Epidemic. Microbicide Trials Network, Pittsburgh, PA. http://www.mtnstopshiv.org/news/studies/mtn003.
49. Dezzutti CS, Uranker K, Bunge KE, Richardson-Harman N, Macio I, Hillier SL. 2013. HIV-1 infection of female genital tract tissue for use in prevention studies: ex vivo challenge using female tissue. J. Acquir. Immune Defic. Syndr. 63:548-554. http://dx.doi.org/10.1097/QAI.0b013e3 18291f331.